UBS Group Portfolio holdings
UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.12B |
| 2 |
Apple
AAPL
|
+$1.08B |
| 3 |
Microsoft
MSFT
|
+$1.05B |
| 4 |
Nike
NKE
|
+$1.03B |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$821M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$389M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$383M |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$348M |
| 4 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$263M |
| 5 |
NRG Energy
NRG
|
+$237M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.8% |
| 2 | Financials | 8.25% |
| 3 | Healthcare | 6.4% |
| 4 | Consumer Discretionary | 5.85% |
| 5 | Communication Services | 4.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
5626
Limoneira
LMNR
$251M
| $206K | ﹤0.01% |
9,900
-12,462
| -56% | -$251K |
|
5627
AdvisorShares Pure US Cannabis ETF
MSOS
$880M
| $206K | ﹤0.01% |
28,092
-256,441
| -90% | -$2.24M |
|
5628
AXT Inc
AXTI
$5.8B
| $206K | ﹤0.01% |
60,826
+48,346
| +387% | +$169K |
|
5629
RPC Inc
RES
$1.3B
| $206K | ﹤0.01% |
32,885
-65,642
| -67% | -$459K |
|
5630
Adaptive Biotechnologies
ADPT
$3.97B
| $205K | ﹤0.01% |
56,631
-86,984
| -61% | -$276K |
|
5631
PUT
Itaú Unibanco
ITUB
$87.5B
| $204K | ﹤0.01% |
39,655
| – | – |
|
|
SHOE
5632
Shoe Station Group
SHOE
$428M
| $204K | ﹤0.01% |
5,532
-4,663
| -46% | -$166K |
|
|
NXDR
5633
Nextdoor Holdings
NXDR
$986M
| $204K | ﹤0.01% |
73,384
-556,951
| -88% | -$1.29M |
|
5634
ATN International
ATNI
$492M
| $204K | ﹤0.01% |
8,928
-3,059
| -26% | -$74.5K |
|
5635
Superior Group of Companies
SGC
$225M
| $203K | ﹤0.01% |
10,755
+9,227
| +604% | +$170K |
|
5636
Ryde Group
RYDE
$150M
| $202K | ﹤0.01% |
+33,172
| New | +$187K |
|
5637
E.W. Scripps
SSP
$304M
| $202K | ﹤0.01% |
64,383
+12,433
| +24% | +$39.4K |
|
5638
The Honest Company
HNST
$586M
| $202K | ﹤0.01% |
69,008
+67,152
| +3,618% | +$200K |
|
|
SRDX
5639
DELISTED
Surmodics
SRDX
| $201K | ﹤0.01% |
4,793
-9,882
| -67% | -$337K |
|
|
LX
5640
LexinFintech Holdings
LX
$241M
| $200K | ﹤0.01% |
121,448
+90,399
| +291% | +$160K |
|
|
SHYF
5641
DELISTED
The Shyft Group
SHYF
| $200K | ﹤0.01% |
16,893
-448,054
| -96% | -$5.38M |
|
5642
Domo
DOMO
$184M
| $200K | ﹤0.01% |
25,923
-11,942
| -32% | -$89.3K |
|
|
GTHX
5643
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $200K | ﹤0.01% |
87,637
+87,329
| +28,354% | +$334K |
|
5644
Red Violet
RDVT
$924M
| $200K | ﹤0.01% |
7,858
-7,126
| -48% | -$144K |
|
5645
UroGen Pharma
URGN
$2.29B
| $199K | ﹤0.01% |
11,887
-30,980
| -72% | -$441K |
|
5646
Paysafe
PSFE
$375M
| $199K | ﹤0.01% |
11,240
-30,817
| -73% | -$513K |
|
5647
ProShares Ultra Energy
DIG
$76.9M
| $199K | ﹤0.01% |
4,707
+3,869
| +462% | +$171K |
|
5648
Bar Harbor Bankshares
BHB
$666M
| $198K | ﹤0.01% |
7,368
-10,521
| -59% | -$269K |
|
|
DFP
5649
Flaherty & Crumrine Dynamic Preferred and Income Fund
DFP
$427M
| $197K | ﹤0.01% |
10,284
+611
| +6% | +$11.4K |
|
5650
Oculis Holding
OCS
$704M
| $197K | ﹤0.01% |
16,500
+15,403
| +1,404% | +$183K |
|
Similar funds
UBS Group's Q2 2024 Portfolio in Review
As of Q2 2024, UBS Group held 10,501 positions worth $405B, up 0.81% from $402B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
UBS Group's Q2 2024 filing shows 1,231 new, 3,688 increased, 4,131 reduced and 1,043 closed positions. Its largest new stake was SLB Ltd: 10,925,731 shares worth $515M. The largest sale was BioMarin Pharmaceuticals, an estimated $389M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 15% a quarter earlier, followed by Financials and Healthcare.
- UBS Group's largest Q2 2024 buy was SLB Ltd: 10,925,731 shares worth $515M.
- UBS Group added most to NVIDIA in Q2 2024, an estimated $1.12B increase.
- UBS Group's biggest Q2 2024 reduction was BioMarin Pharmaceuticals, cutting an estimated $389M.
- UBS Group fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $263M.
- UBS Group's ten largest holdings make up 18% of its $405B portfolio in Q2 2024.
- UBS Group opened 1,231 new positions and closed 1,043 in Q2 2024.
- UBS Group's portfolio value rose 0.81% quarter-over-quarter to $405B.
Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.